AMAG Pharmaceuticals, Inc. AMAG Cash Flow

Amag pharmaceuticals, inc. (AMAG)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	0	88,548	-	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from operating activities:
Net loss
-368,863	-466,456	-288,805	-234,348	-133,603	-65,761	-40,024	-222,926	-216,910	-199,228	-213,245	-44,986	-31,516	-2,483	15,275	-21,506	12,348	32,779	168,586	190,628	155,823	135,817	-10,845	-12,448	-12,809	-9,602	-9,634	-13,456	-8,229	-16,750	-31,645	-44,309	-67,190	-77,069	-78,268	-78,633	-80,395	-81,153	0	0	0
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
33,267	27,324	28,092	55,129	117,113	172,223	224,599	222,158	187,029	155,538	119,867	118,218	108,236	99,886	86,717	75,959	74,228	69,103	57,675	40,979	21,341	6,984	805	2,126	2,597	3,085	3,277	3,001	3,183	3,084	3,312	2,641	2,445	2,536	2,590	2,548	2,477	2,405	0	0	0
Provision for bad debt expense
239	0	-88	-190	199	678	1,103	2,027	3,725	3,852	4,503	5,890	1,590	3,209	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premium/discount on purchased securities
64	95	73	57	7	-87	-180	-227	-256	-302	-324	-441	-560	-624	-1,165	-1,845	-2,273	-2,152	-1,762	-1,482	-1,472	-2,080	-2,505	-2,645	-2,741	-2,758	-2,703	-2,714	-2,723	-2,808	-3,042	-3,261	-3,537	-3,639	-3,553	-3,262	-2,514	-1,679	0	0	0
Write-down of inventory
20,416	19,800	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,309	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash equity-based compensation expense
18,193	19,198	19,698	18,201	19,256	19,916	20,205	23,117	23,419	23,664	23,792	22,870	22,161	22,543	22,474	21,895	20,729	17,237	14,044	11,102	9,363	8,625	8,271	7,990	7,651	8,004	7,598	7,983	7,622	7,024	6,552	6,204	7,248	10,038	12,585	12,383	14,697	14,523	0	0	0
Non-cash IPR&D expense
0	18,029	18,029	18,029	18,029	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount and debt issuance costs
15,463	15,242	15,166	15,320	15,561	15,658	15,619	15,567	15,066	14,395	13,690	12,844	12,377	12,105	11,931	11,818	11,915	11,379	10,802	9,719	8,420	6,870	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gains on marketable securities, net
274	265	0	0	0	-	-	-	-	-70	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Gains) on sale of assets held for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on sale of investments, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	40	0	0	0	-	-	-	-	-193	-188	-598	405	408	0	0	0
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent consideration
-264	-270	-448	-444	-50,239	-49,607	-49,719	-99,656	-48,103	-47,686	-26,565	27,070	21,670	25,683	4,852	4,031	6,728	4,271	6,379	-220	1,129	-681	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash lease expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income taxes
0	-	0	0	0	-	0	0	0	-	0	0	-12,444	-	-9,977	-20,007	-2,070	5,007	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash lease expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of assets
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
23,392	18,816	-7,591	-20,435	-5,931	-16,995	-1,086	26,476	18,438	14,978	32,185	29,265	4,068	9,906	-552	-528	18,194	36,913	16,456	10,522	11,143	-3,588	2,095	2,091	1,596	432	1,415	2,712	2,241	478	294	965	-231	147	-579	-9,417	-8,495	-21,565	0	0	0
Inventories
19,050	19,253	10,865	5,000	6,961	454	-1,856	-37	-1,606	2,331	1,586	3,781	601	2,355	5,593	3,929	10,720	5,237	-123	-180	-4,487	1,360	4,176	4,302	5,395	1,040	-1,447	-3,086	-3,772	-4,069	-1,989	-1,471	-2,639	-821	-2,576	-140	3,862	6,675	0	0	0
Receivable from collaboration
-	-	-	-	-	-	-	-	-	-	-	-	-	-428	0	-5,615	182	-4,090	-933	5,384	-203	4,239	682	-138	94	15	-527	-14,765	-262	-165	585	14,262	-481	-13	0	0	0	-	-	-	-
Prepaid and other current assets
-14,977	113	31,273	10,903	23,957	6,097	-288	1,800	7,465	2,222	-3,979	-3,190	-8,696	-4,095	-2,830	-430	2,120	-4,034	-4,453	-7,087	-6,421	-2,331	-293	-837	-1,809	-2,817	-1,727	1,456	479	-75	1,841	-1,365	-1,001	-1,661	-1,907	637	1,841	2,477	0	0	0
Other long-term assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
1,644	52,747	24,804	-24,564	-31,510	-32,568	-17,423	3,593	51,830	16,834	59,074	85,053	51,062	49,037	31,829	2,345	-3,623	7,876	6,594	21,440	16,647	10,694	1,390	-156	243	-5,730	-5,842	-11,738	-16,806	-12,195	-16,771	-6,261	2,743	1,698	7,448	229	1,939	2,745	0	0	0
Deferred revenues
-	-	-	-	-	8,658	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues
-	-	-	-	-	-	-	-	-	-	-	-	16,872	-	35,266	39,383	-1,667	-22,197	-37,300	-47,582	-16,122	-8,384	-8,354	-8,089	-7,953	-6,694	6,581	7,177	7,620	7,912	-5,192	-6,096	-6,167	-6,353	-7,834	-11,277	46,927	46,697	0	0	0
Other assets and liabilities
2,935	1,800	-974	-1,261	-1,679	-95	-75	77	522	1,223	2,636	3,029	1,109	30	-5,730	-5,679	-6,151	-7,244	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-82,397	-125,696	-129,824	-120,780	-74,800	60,800	104,841	133,292	166,824	106,596	149,168	194,020	205,110	246,222	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities
81,631	98,321	110,517	87,724	95,062	85,342	75,577	87,978	184,670	294,957	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
23,345	14,815	40,371	58,045	83,669	89,956	80,755	88,726	19,110	127,249	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	196	208	183	-246	-408	-433	-419	-405	-391	-376	-363	-349	-335	-321	-307	-294	0	0	0
Total adjustments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	17,535	23,951	8,466	15,593	-7,980	-11,547	13,504	13,265	22,999	15,734	70,090	79,626	0	0	0
Net cash provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-8,254	-6,707	-8,135	-6,774	7,901	10,495	237	-1,157	-39,625	-55,856	-53,686	-63,804	0	0	0	-	-	-	-
Proceeds from sales or maturities of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	206,678	245,002	233,007	208,966	238,997	181,326	198,321	223,568	80,168	90,969	102,073	106,030	114,975	111,594	126,220	133,061	144,539	155,296	143,272	141,095	148,890	163,637	186,456	160,079	0	0	0
Purchase of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	240,854	232,469	394,277	424,759	326,080	307,503	132,596	63,747	90,164	92,722	106,186	115,046	132,730	122,881	131,107	149,406	138,183	148,851	129,426	126,585	0	0	0	-	-	-	-
Change in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-2,883	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from the sale of assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital expenditures
818	2,544	2,719	2,888	3,405	2,534	4,328	7,869	9,253	8,988	0	0	0	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	23	47	139	342	478	507	538	792	1,082	1,223	0	0	0
Capital expenditures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,885	1,259	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-1,092	20,962	-2,573	536,094	517,291	502,155	509,797	-17,917	100,507	102,920	107,357	102,774	-35,497	-72,704	-38,740	-673,187	-845,144	-899,041	-1,364,731	-721,905	-529,952	-432,942	-8,011	-965	-6,518	-13,935	-21,818	-14,144	-4,542	-16,392	6,217	6,103	13,368	14,003	26,093	6,255	-126,587	-103,741	0	0	0
Cash flows from financing activities:
Proceeds from sale of assets held for sale
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	407,477	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	165,559	0	0	0
Long-term debt principal payments
-	-	-	-	-	-	-	-	-	-	332,500	336,875	17,502	17,502	13,127	319,575	323,699	327,509	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Convertible Debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments to settle convertible notes
0	21,417	21,417	21,417	21,417	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of Debt Issuance Costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,760	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of contingent consideration
72	72	82	86	92	119	39,715	39,734	39,754	39,793	92,083	92,100	92,148	92,130	346	415	437	456	406	370	323	270	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25,620	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of convertible bond hedges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for repurchases of common stock
0	13,730	13,730	13,730	13,730	0	0	0	0	-	-	-	-	20,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of common stock options
-3	30	1,276	2,438	3,791	3,881	3,306	3,364	2,992	3,021	0	0	0	-	-	-	9,087	-	21,072	18,126	14,201	8,499	2,557	2,919	2,131	1,277	0	0	0	-	-	-	-	121	25	263	571	1,337	0	0	0
Payments of employee tax withholding related to equity-based compensation
1,404	1,830	1,867	2,068	1,970	2,682	2,740	2,619	3,722	2,696	2,588	2,595	1,797	2,171	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
27	-35,513	-34,969	-537,066	-536,472	-501,974	-587,544	-105,439	-290,285	-293,644	-303,830	-287,725	-120,248	-127,918	-45,110	699,486	711,571	912,469	1,256,219	516,394	520,953	513,838	181,473	181,927	181,724	1,402	0	0	0	-	-	-	-	629	569	807	1,463	167,788	0	0	0
Net decrease in cash, cash equivalents, and restricted cash
-83,462	-140,247	-167,366	-121,752	-93,981	60,981	27,094	9,936	-22,954	-84,128	-47,305	9,069	49,365	45,600	137,749	161,226	-40,412	109,409	-28,624	-112,173	42,885	92,310	165,208	174,255	167,071	-19,307	-11,954	-2,876	-3,774	-17,181	-32,877	-49,278	-39,699	-49,172	-28,607	-55,837	-135,429	62,520	0	0	0
Supplemental data for cash flow information:
Cash (refunded) paid for taxes
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for taxes
-	-	-	-	-	-	0	0	5,224	-	4,263	4,597	5,514	5,309	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
10,400	10,667	10,678	30,053	30,053	48,757	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Settlement of note receivable in connection with Perosphere acquisition
0	10,000	10,000	10,000	10,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-